All In Biotech

Drug Trial Radar · NCT07298330

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jan 14, 2026

Primary completion

Aug 2026

Study completion Jan 2029

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment.

Conditions

  • Chronic Hepatitis D Infection

Interventions

  • Brelovitug 300 mgDrug

    Route of administration- Subcutaneous Injection

  • Brelovitug 900 mgDrug

    Route of administration- Subcutaneous Injection

  • Delayed Treatment with Brelovitug 300mgDrug

    Route of administration- Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with a composite endpoint of virologic response and ALT normalization at Week 24 in brelovitug arms compared to response at Week 12 of delayed-treatment armTime frame: Week 24

Locations

27 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California, Davis

    Davis, California

  • Kaiser Permanente Medical Center

    Sacramento, California

  • Quest Clinical Research

    San Francisco, California

  • Denver Health Medical Center

    Denver, Colorado

  • Alliance Clinical, Las Vegas

    Las Vegas, Nevada

  • Cleveland Clinic

    Cleveland, Ohio

  • Prime Clinical Research Inc

    Mansfield, Texas

  • University of Utah

    Salt Lake City, Utah

  • Erasme Hospital

    Brussels, Belgium

  • University Hospital Antwerp (UZA)

    Edegem, Belgium

  • University Hospital Center Sart-Tilman

    Liège, Belgium

  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda

    Sofia, Bulgaria

  • Hospital Service LTD

    Kutaisi, Georgia

  • Diakori LLC

    Tbilisi, Georgia

  • JSC T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center

    Tbilisi, Georgia

  • LTD Academician Vakhtang Bochorishvili Clinic

    Tbilisi, Georgia

  • Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases

    Budapest, Hungary

  • Fejer County St. Gyorgy University Teaching Hospital

    Székesfehérvár, Hungary

  • Soroka University Medical Center

    Beersheba, Israel

  • HaEmek Medical Center

    Haifa, Israel

  • Aga Khan University & Hospital

    Karachi, Karachi, Pakistan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • E-Da Hospital

    Kaohsiung City, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Limited Liability Company "Medical Center Health and Rehabilitation "100 Percent Life"

    Poltava, Ukraine

  • Public Non-Profit Enterprise "Central City Hospital" of Rivne City Council

    Rivne, Ukraine

  • Research Institute of Virology of the Republic of Uzbekistan

    Tashkent, Uzbekistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.